Drug
Gefapixant clinical trials
Also written MK-7264 and AF-219.
Keep track of what changes. Save the Gefapixant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2015 (8)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 8 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 2
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (14) · Merck Sharp & Dohme LLC (11) · Nagoya City University (1) · Stuart Mazzone (1)
Studies
Open first, then newest update. How each study uses Gefapixant is read from its arms, and is right about nine times in ten.
Testing it · 27
- The Real-world Treatment Satisfaction by Gefapixiant in RCCRecruitingNot applicableNagoya City UniversityNCT06542484Written as Gefapixant Citrate
- Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic CoughRecruitingEarly Phase 1Stuart MazzoneNCT05813223Written as Gefapixant
- Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)CompletedPhase 3Merck Sharp & Dohme LLCNCT04193176Written as Gefapixant
- A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)CompletedPhase 2Merck Sharp & Dohme LLCNCT03654326Written as Gefapixant
- Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)CompletedPhase 1Merck Sharp & Dohme LLCNCT03882801Written as Gefapixant
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China ExtensionCompletedPhase 3Merck Sharp & Dohme LLCNCT04525885Written as Gefapixant 45 mg twice daily (BID)
- Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)CompletedPhase 3Merck Sharp & Dohme LLCNCT04193202Written as Gefapixant
- The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)CompletedPhase 1Merck Sharp & Dohme LLCNCT03108924Written as Gefapixant
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) FormulationsCompletedPhase 1Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02492776Written as Gefapixant
- A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)CompletedPhase 1Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02229877Written as Gefapixant
- A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)CompletedPhase 3Merck Sharp & Dohme LLCNCT03696108Written as Gefapixant
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)CompletedPhase 3Merck Sharp & Dohme LLCNCT03449147Written as Gefapixant 15 mg BID
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)CompletedPhase 3Merck Sharp & Dohme LLCNCT03449134Written as Gefapixant
- A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02502097Written as Gefapixant
- Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02397460Written as Gefapixant
- A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01993329Written as Gefapixant 50 mg
- A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01432730Written as Gefapixant
- A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02349425Written as Gefapixant
- The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)TerminatedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01569438Written as Gefapixant
- A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)CompletedPhase 2Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02612610Written as Gefapixant
Codes
What other systems call Gefapixant · ClinicalTrials.gg INT000214
- MeSH (NLM) C000597312GefapixantOne source NLM
- UNII (FDA) 6K6L7E3F1LGEFAPIXANTConfirmed FDA, NLM, Wikidata
- Wikidata Q94572860gefapixantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166945GefapixantOne source FDA
- DrugBank DB15097One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000597312 | Gefapixant | One source NLM |
| UNII (FDA) | 6K6L7E3F1L | GEFAPIXANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q94572860 | gefapixant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166945 | Gefapixant | One source FDA |
| DrugBank | DB15097 | — | One source Wikidata |
Also registered as gefapixant citrate (UNII DFK0FC2VVV).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.